Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 46, 2016, Pages 13168-13173

  Carroll, Virginia A ^a   Lafferty, Mark K ^a   Marchionni, Luigi ^b   Bryant, Joseph L ^a   Gallo, Robert C ^a   Garzino Demo, Alfredo ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

B cell lymphoma; HIV 1; Matrix protein p17; RAG; Transgenic mice

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IGLL1 PROTEIN; MATRIX PROTEIN; PROTEIN P17; RAG1 PROTEIN; RAG2 PROTEIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; VPREB1 PROTEIN; VPREB3 PROTEIN; DNA BINDING PROTEIN; GAG PROTEIN; HOMEODOMAIN PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; RAG-1 PROTEIN; V(D)J RECOMBINATION ACTIVATING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BONE MARROW; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPH NODE; LYMPHOMA CELL; LYMPHOMAGENESIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; TRANSGENIC MOUSE; TUMOR CELL; ANIMAL; B LYMPHOCYTE; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM;

ANIMALS; B-LYMPHOCYTES; BONE MARROW; DNA-BINDING PROTEINS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HIV ANTIGENS; HIV-1; HOMEODOMAIN PROTEINS; HUMANS; LYMPH NODES; LYMPHOMA, B-CELL; MICE, TRANSGENIC;

EID: 84995554299     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1615258113     Document Type: Article

References (59)

1. Hleyhel M, et al.; French Hospital Database on HIV-ANRS CO4 Cohort (2013) Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 57(11): 1638-1647.
2. Gaidano G, Pastore C, Lanza C, Mazza U, Saglio G (1994) Molecular pathology of AIDS-related lymphomas: Biologic aspects and clinicopathologic heterogeneity. Ann Hematol 69(6):281-290.
3. Cesarman E (2013) Pathology of lymphoma in HIV. Curr Opin Oncol 25(5):487-494.
4. Dunleavy K, Wilson WH (2013) Implications of the shifting pathobiology of AIDSrelated lymphoma. J Natl Cancer Inst 105(16):1170-1171.
5. Ambinder RF (2007) Epstein-Barr virus and Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 2007(1):204-209.
6. Gaidano G, et al. (1997) Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia. Leuk Lymphoma 24(3-4):257-266.
7. Chao C, et al. (2012) Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma. Clin Cancer Res 18(17): 4702-4712.
8. Liapis K, et al. (2013) The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 122(3):424-433.
9. Dunleavy K, Wilson WH (2012) How I treat HIV-associated lymphoma. Blood 119(14): 3245-3255.
10. Gopal S, et al. (2013) Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 105(16):1221-1229.
11. Molyneux EM, et al. (2012) Burkitt's lymphoma. Lancet 379(9822):1234-1244.
12. Dolcetti R, et al. (2015) Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc Natl Acad Sci USA 112(46):14331-14336.
13. Carroll V, Garzino-Demo A (2015) HIV-associated lymphoma in the era of combination antiretroviral therapy: Shifting the immunological landscape. Pathog Dis 73(7):ftv044.
14. Popovic M, et al. (2005) Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 102(41):14807-14812.
15. Vendrame E, et al. (2014) Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 23(2):343-349.
16. Epeldegui M, et al. (2007) Elevated expression of activation-induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. AIDS 21(17):2265-2270.
17. Huysentruyt LC, McGrath MS (2010) The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol 87(4):627-632.
18. Giagulli C, et al. (2011) Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 6(3):e17831.
19. Caccuri F, et al. (2014) Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol 88(10):5706-5717.
20. Caccuri F, et al. (2012) HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci USA 109(36):14580-14585.
21. Caccuri F, et al. (2014) HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis. Arterioscler Thromb Vasc Biol 34(4):846-856.
22. Basta D, et al. (2015) Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. Pathog Dis 73(8):ftv062.
23. Zoufaly A, et al.; ClinSurv Study Group (2009) Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 200(1):79-87.
24. Dickie P, et al. (1991) HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185(1):109-119.
25. Curreli S, et al. (2013) B cell lymphoma in HIV transgenic mice. Retrovirology 10:92.
26. Kopp JB, et al. (1992) Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 89(5):1577-1581.
27. Kopp JB, et al. (1993) Cutaneous disorders and viral gene expression in HIV-1 transgenic mice. AIDS Res Hum Retroviruses 9(3):267-275.
28. He B, et al. (2006) HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 176(7):3931-3941.
29. Qiao X, et al. (2006) Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 7(3):302-310.
30. Xu W, et al. (2009) HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 10(9):1008-1017.
31. Wiley EL, Nightingale SD (1994) Opportunistic events and p17 expression in the bone marrow of human immunodeficiency virus-infected patients. J Infect Dis 169(3): 617-620.
32. Nagasawa T (2015) CXCL12/SDF-1 and CXCR4. Front Immunol 6:301.
33. Hardy RR, Hayakawa K (2001) B cell development pathways. Annu Rev Immunol 19: 595-621.
34. Jinquan T, et al. (1997) Chemotaxis and IL-8 receptor expression in B cells from normal and HIV-infected subjects. J Immunol 158(1):475-484.
35. Fan X, et al. (2007) Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem 282(16):11658-11666.
36. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
37. Fiorentini S, et al. (2008) HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci USA 105(10):3867-3872.
38. Bresnick EH, Lee HY, Fujiwara T, Johnson KD, Keles S (2010) GATA switches as developmental drivers. J Biol Chem 285(41):31087-31093.
39. Liu Y, Hernandez AM, Shibata D, Cortopassi GA (1994) BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 91(19):8910-8914.
40. Vanasse GJ, et al. (1999) Genetic pathway to recurrent chromosome translocations in murine lymphoma involves V(D)J recombinase. J Clin Invest 103(12): 1669-1675.
41. Morton LM, et al. (2014) Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and-uninfected patients in the prehighly active antiretroviral therapy and pre-rituximab era. Leuk Lymphoma 55(3): 551-557.
42. Bories JC, Cayuela JM, Loiseau P, Sigaux F (1991) Expression of human recombination activating genes (RAG1 and RAG2) in neoplastic lymphoid cells: Correlation with cell differentiation and antigen receptor expression. Blood 78(8):2053-2061.
43. Meru N, Jung A, Lisner R, Niedobitek G (2001) Expression of the recombination activating genes (RAG1 and RAG2) is not detectable in Epstein-Barr virus-associated human lymphomas. Int J Cancer 92(1):75-78.
44. Hillion S, Dueymes M, Youinou P, Jamin C (2007) IL-6 contributes to the expression of RAGs in human mature B cells. J Immunol 179(10):6790-6798.
45. Giachino C, Padovan E, Lanzavecchia A (1998) Re-expression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphocytes. Eur J Immunol 28(11):3506-3513.
46. Han S, Zheng B, Schatz DG, Spanopoulou E, Kelsoe G (1996) Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science 274(5295): 2094-2097.
47. Gentleman RC, et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5(10):R80.
48. McCall MN, Jaffee HA, Irizarry RA (2012) fRMA ST: Frozen robust multiarray analysis for Affymetrix Exon and Gene ST arrays. Bioinformatics 28(23):3153-3154.
49. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3.
50. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 57(1):289-300.
51. Gower JC (1966) Some distance properties of latent root and vector methods used in multivariate analysis. Biometrika 53(3/4):325-338.
52. Kortenhorst MS, et al. (2013) Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics 8(9):907-920.
53. Ross AE, et al. (2011) Molecular effects of genistein on male urethral development. J Urol 185(5):1894-1898.
54. Guerrero-Preston R, et al. (2014) Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics 9(7):1031-1046.
55. Iglesias-Ussel M, Vandergeeten C, Marchionni L, Chomont N, Romerio F (2013) High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol 87(16):9148-9158.
56. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res 32(Database issue):D277-D280.
57. Croft D, et al. (2014) The Reactome pathway knowledgebase. Nucleic Acids Res 42(Database issue):D472-D477.
58. Ashburner M, et al.; The Gene Ontology Consortium (2000) Gene Ontology: Tool for the unification of biology. Nat Genet 25(1):25-29.
59. Xie X, et al. (2005) Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 434(7031):338-345.